Nonmotor Fluctuations in Parkinson's Disease.
暂无分享,去创建一个
[1] Andrew Evans,et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Onofrj,et al. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features , 2008, Neuropsychiatric disease and treatment.
[3] Paolo Barone,et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[4] K. Chaudhuri,et al. The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[5] B. Ford. Pain in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[6] J. D. Parkes,et al. "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.
[7] William W. McDonald,et al. Depression rating scales in Parkinson's disease: Critique and recommendations , 2007, Movement disorders : official journal of the Movement Disorder Society.
[8] S. Cheon,et al. Nonmotor symptoms more closely related to Parkinson's disease: Comparison with normal elderly , 2013, Journal of the Neurological Sciences.
[9] S. Snider,et al. Sensory symptoms , 1985, Neurology.
[10] G. Ebersbach,et al. Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. , 2015, Journal of Parkinson's disease.
[11] T. Müller. Tolcapone addition improves Parkinson’s disease associated nonmotor symptoms , 2014, Therapeutic advances in neurological disorders.
[12] R. M. Stewart,et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. , 2008, Parkinsonism & related disorders.
[13] F. Carrillo,et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease , 2014, Journal of Neurology.
[14] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[15] Jean Régis,et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[16] A. Rajput,et al. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.
[17] E. Mohr,et al. Dopamine and memory function in Parkinson's disease , 1989, Movement disorders : official journal of the Movement Disorder Society.
[18] M. Mark,et al. Drenching sweats as an off phenomenon in parkinson's disease: Treatment and relation to plasma levodopa profile , 1995, Annals of neurology.
[19] A M Stiggelbout,et al. Assessment of cognition in Parkinson’s disease , 2003, Neurology.
[20] P. James. An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.
[21] [Micturition disturbances in Parkinson's disease. Clinical and urodynamic evaluation]. , 2002, Neurologia i neurochirurgia polska.
[22] M. Cosio,et al. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease. , 1989, Chest.
[23] N. Tuncer,et al. The Clinical Profile of Nonmotor Fluctuations in Parkinson's Disease Patients , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[24] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[25] Angelo Antonini,et al. Wearing‐off scales in Parkinson's disease: Critique and recommendations , 2011, Movement disorders : official journal of the Movement Disorder Society.
[26] A. Lang,et al. The spectrum of levodopa‐related fluctuations in Parkinson's disease , 1993, Neurology.
[27] M Zappia,et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease , 2009, Neurology.
[28] H. Reichmann,et al. Nonmotor fluctuations in Parkinson disease , 2013, Neurology.
[29] G. Ebersbach,et al. Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. , 2016, Journal of Parkinson's disease.
[30] W. Weiner,et al. Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease , 2010, Neurology.
[31] P. Krack,et al. The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations , 2016, Movement disorders : official journal of the Movement Disorder Society.
[32] J. Lou. Fatigue in Parkinson's disease and potential interventions. , 2015, NeuroRehabilitation.
[33] T. Anderson,et al. The MoCA , 2010, Neurology.
[34] E. Chudler,et al. The role of the basal ganglia in nociception and pain , 1995, Pain.
[35] A. Lang,et al. Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease , 2011, Parkinson's disease.
[36] P. Stanzione,et al. Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[37] P Soliveri,et al. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[38] K. Chaudhuri,et al. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? , 2013, Journal of Neural Transmission.
[39] J. Cummings,et al. Parkinson's disease, depression, and the on-off phenomenon. , 1989, Psychosomatics.
[40] K. Chaudhuri,et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study , 2014, BMC Neurology.
[41] A. Rajput,et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease , 2013 .
[42] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[43] L. Tremblay,et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.
[44] A. Albanese,et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. , 2014, Parkinsonism & related disorders.
[45] A. Lees,et al. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.
[46] L. Defebvre,et al. Apathy in untreated early‐stage Parkinson disease: Relationship with other non‐motor symptoms , 2014, Movement disorders : official journal of the Movement Disorder Society.
[47] Mark Stacy,et al. Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment , 2005, Movement disorders : official journal of the Movement Disorder Society.
[48] T. Anderson,et al. Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER) , 2010, Movement disorders : official journal of the Movement Disorder Society.
[49] H. Reichmann,et al. Quantitative assessment of non-motor fluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS) , 2015, Journal of Neural Transmission.
[50] J. Sage,et al. Nonmotor fluctuations in patients with Parkinson's disease , 1996, Neurology.
[51] M. Stacy,et al. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease , 2007, Journal of Neural Transmission.
[52] A. Lang,et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, Advances in neurology.
[53] A. Lang,et al. Akathisia in idiopathic Parkinson's disease. , 1987, Neurology.
[54] S. Factor,et al. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[55] A. Mendes,et al. Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression , 2015, Behavioural neurology.
[56] P. Svenningsson,et al. EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[57] J. Nutt,et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease , 1995, Neurology.
[58] J. Nutt,et al. Mood response to levodopa infusion in early Parkinson's disease. , 1998, Neurology.
[59] E. Dietrichs,et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. , 2014, Parkinsonism & related disorders.
[60] R. Pahwa,et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose , 2007, Journal of the Neurological Sciences.
[61] M. T. Pellecchia,et al. Gender and non motor fluctuations in Parkinson's disease: A prospective study. , 2016, Parkinsonism & related disorders.
[62] Pablo Martinez-Martin,et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients , 2007, Movement disorders : official journal of the Movement Disorder Society.
[63] K. Chaudhuri,et al. New clinical trials for nonmotor manifestations of Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[64] C. Marsden,et al. Mood swings associated with the ‘on—off’ phenomenon in Parkinson's disease , 1987, Psychological Medicine.
[65] A. Benabid,et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.
[66] A. Kishore,et al. Do nonmotor symptoms in Parkinson's disease differ from normal aging? , 2011, Movement disorders : official journal of the Movement Disorder Society.
[67] L. Grégoire,et al. Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[68] O Rascol. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .
[69] J. Friedman,et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. , 2013, Parkinsonism & related disorders.
[70] C. Marsden,et al. PAINFUL PARKINSON'S DISEASE , 1986, The Lancet.
[71] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[72] A. Zenzola,et al. Fatigue in Parkinson’s disease , 2003, Neurological Sciences.
[73] P. Odin,et al. Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances. , 2016, Current opinion in neurology.
[74] D. Bailey,et al. 18F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease , 2002, Synapse.
[75] G. Deuschl,et al. Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.
[76] W. Poewe,et al. High‐speed memory scanning in Parkmson's disease: Adverse effects of levodopa , 1991, Annals of neurology.
[77] M. Ceccaldi,et al. Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.
[78] W. Oertel,et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients , 1997, Neurology.
[79] L. Seeberger,et al. A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.
[80] P. Rabins,et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[81] E. Dietrichs,et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. , 2015, Parkinsonism & related disorders.
[82] R. Cools. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease , 2006, Neuroscience & Biobehavioral Reviews.
[83] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[84] Z. Wszolek,et al. Anorectal function in fluctuating (on‐off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography , 1995, Movement disorders : official journal of the Movement Disorder Society.
[85] B. Bergamasco,et al. Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[86] D. Ye,et al. Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment , 2016, Journal of neuroscience research.
[87] J. Jankovic,et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.
[88] M. Costa,et al. Anxiety, depression, and quality of life in Parkinson's disease. , 2009, The Journal of neuropsychiatry and clinical neurosciences.
[89] C. Marsden,et al. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[90] J. Groothoff,et al. The associations between fatigue, apathy, and depression in Parkinson's disease , 2015, Acta neurologica Scandinavica.
[91] G. Deuschl,et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. , 2015, Parkinsonism & related disorders.
[92] Z. Pei,et al. Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[93] A. Berardelli,et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. , 2008, Archives of neurology.
[94] W. Poewe,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[95] J. Lou,et al. Fatigue in Parkinson's disease: A review , 2007, Movement disorders : official journal of the Movement Disorder Society.
[96] R. Hauser,et al. Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson Disease , 2006, Clinical neuropharmacology.
[97] S. Calzetti,et al. Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[98] C. Marsden,et al. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.
[99] P. Martínez-Martín,et al. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease , 2017, Journal of the Neurological Sciences.
[100] A. Williams,et al. Stridor during dystonic phases of Parkinson's disease. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[101] Anette Schrag,et al. Quality of life and depression in Parkinson's disease , 2006, Journal of the Neurological Sciences.
[102] G. Ebersbach,et al. Tolcapone improves sleep in patients with advanced Parkinson's disease (PD). , 2010, Archives of gerontology and geriatrics.
[103] Harald Binder,et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. , 2014, Parkinsonism & related disorders.
[104] V. Kostic,et al. Mild Cognitive Impairment in Early Parkinson's Disease Using the Movement Disorder Society Task Force Criteria: Cross-Sectional Study in Hoehn and Yahr Stage 1 , 2015, Dementia and Geriatric Cognitive Disorders.
[105] R. Hauser,et al. Parkinson's disease home diary: Further validation and implications for clinical trials , 2004, Movement disorders : official journal of the Movement Disorder Society.
[106] J. Friedman,et al. Fatigue in levodopa-naïve subjects with Parkinson disease , 2008, Neurology.
[107] C. Wolfson,et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). , 2012, Parkinsonism & related disorders.
[108] F. Raudino. Non motor off in Parkinson's disease , 2001, Acta neurologica Scandinavica.
[109] Lucile Brun,et al. Non-motor fluctuations in Parkinson's disease: Prevalence, characteristics and management in a large cohort of parkinsonian outpatients , 2014, Clinical Neurology and Neurosurgery.
[110] G. Deuschl,et al. A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.
[111] C. Adler,et al. Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations , 1997, Neurology.
[112] W. Jost. Autonomic dysfunctions in idiopathic Parkinson's disease , 2003, Journal of Neurology.
[113] M. Swash,et al. Anal sphincter dysfunction in Parkinson's disease. , 1989, Archives of neurology.
[114] Marianna Amboni,et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.
[115] R. Helme,et al. Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge. , 2012, Parkinsonism & Related Disorders.
[116] E. Tolosa,et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.
[117] J. Jankovic,et al. Respiratory dyskinesia in Parkinson's disease , 1986, Neurology.
[118] G. Ebersbach,et al. Pain intensity on and off levodopa in patients with Parkinson's disease , 2009, Movement Disorders.
[119] J. Larsen,et al. Fatigue in patients with Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[120] G. Ebersbach,et al. Timing and Kinetics of Nonmotor Fluctuations in Advanced Parkinson's Disease. , 2017, Journal of Parkinson's disease.
[121] K. Dujardin,et al. Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease. , 2016, Journal of Parkinson's disease.
[122] Paul Krack,et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. , 2013, Brain : a journal of neurology.
[123] P. Martínez-Martín. Nonmotor symptoms and health‐related quality of life in early Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[124] O. Rascol,et al. King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation , 2015, Movement disorders : official journal of the Movement Disorder Society.
[125] Pasquale Calabrese,et al. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument , 2008 .
[126] Edo Richard,et al. Apathy in Parkinson's disease: A systematic review and meta‐analysis , 2015, Movement disorders : official journal of the Movement Disorder Society.
[127] K. Safranow,et al. Ophthalmological Features of Parkinson Disease , 2014, Medical science monitor : international medical journal of experimental and clinical research.
[128] Angelo Antonini,et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[129] Pablo Martinez-Martin,et al. The importance of non-motor disturbances to quality of life in Parkinson's disease , 2011, Journal of the Neurological Sciences.
[130] R. Pfeiffer. Autonomic dysfunction in Parkinson's disease , 2012, Expert review of neurotherapeutics.
[131] A. Nieoullon. Dopamine and the regulation of cognition and attention , 2002, Progress in Neurobiology.
[132] R. Duvoisin,et al. Mood changes and “on‐off” phenomena in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[133] Gabriele Schackert,et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. , 2012, Parkinsonism & related disorders.
[134] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[135] S. Nogawa,et al. Clinical features and varieties of non-motor fluctuations in Parkinson's disease: a Japanese multicenter study. , 2013, Parkinsonism & related disorders.